Colibactin-producing Escherichia coli enhance resistance to chemotherapeutic drugs by promoting epithelial to mesenchymal transition and cancer stem cell emergence

References

• Yauch RL, Settleman J. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Curr Opin Genet Dev. 2012;22(1):45–15. doi:10.1016/j.gde.2012.01.003.
   PubMed Web of Science ®Google Scholar
• Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–1134. doi:10.1038/nm.4409.
   PubMed Web of Science ®Google Scholar
• Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018;18(11):669–680. doi:10.1038/s41568-018-0056-x.
   PubMed Web of Science ®Google Scholar
• Savagner P, Yamada KM, Thiery JP. The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor–induced epithelial–mesenchymal transition. J Cell Biol. 1997;137(6):1403–1419. doi:10.1083/jcb.137.6.1403.
   PubMed Web of Science ®Google Scholar
• Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, Del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2(2):76–83. doi:10.1038/35000025.
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–1437. doi:10.1172/JCI36183.
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D’Alessio AC, Young RA, Weinberg RA. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013;154(1):61–74. doi:10.1016/j.cell.2013.06.005.
   PubMed Web of Science ®Google Scholar
• Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, Weinberg RA. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature. 2015;525(7568):256–260. doi:10.1038/nature14897.
   PubMed Web of Science ®Google Scholar
• Beck B, Lapouge G, Rorive S, Drogat B, Desaedelaere K, Delafaille S, Dubois C, Salmon I, Willekens K, Marine J-C. et al. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell. 2015;16(1):67–79. doi:10.1016/j.stem.2014.12.002.
   PubMed Web of Science ®Google Scholar
• Schmidt JM, Panzilius E, Bartsch HS, Irmler M, Beckers J, Kari V, Linnemann JR, Dragoi D, Hirschi B, Kloos UJ. et al. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Rep. 2015;10(2):131–139. doi:10.1016/j.celrep.2014.12.032.
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Corominas-Faja B, Cufí S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, López-Bonet E, Martin ÁG, Menendez JA. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (herceptin). Cell Cycle Georget Tex. 2012;11(21):4020–4032. doi:10.4161/cc.22225.
   PubMed Web of Science ®Google Scholar
• Ren J, Chen Y, Song H, Chen L, Wang R. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem. 2013;114(6):1395–1403. doi:10.1002/jcb.24481.
   PubMed Web of Science ®Google Scholar
• Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan J-P, Kirkpatrick DS, Settleman J. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget. 2014;5(17):7328–7341. doi:10.18632/oncotarget.2397.
   PubMed Web of Science ®Google Scholar
• Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL. et al. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res. 2014;74(20):5878–5890. doi:10.1158/0008-5472.CAN-14-1009.
   PubMed Web of Science ®Google Scholar
• Song K-A, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE. et al. Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(1):197–208. doi:10.1158/1078-0432.CCR-17-1577.
   PubMed Web of Science ®Google Scholar
• Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16(6):488–494. doi:10.1038/ncb2976.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890. doi:10.1016/j.cell.2009.11.007.
   PubMed Web of Science ®Google Scholar
• Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRnas. Nat Cell Biol. 2009;11(12):1487–1495. doi:10.1038/ncb1998.
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Sci. 2013;342(6161):971–976. doi:10.1126/science.1240537.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Sci. 2013;342(6161):967–970. doi:10.1126/science.1240527.
   PubMed Web of Science ®Google Scholar
• Lehouritis P, Cummins J, Stanton M, Murphy CT, McCarthy FO, Reid G, Urbaniak C, Byrne WL, Tangney M. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015;5:14554. doi:10.1038/srep14554.
   PubMed Web of Science ®Google Scholar
• Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Sci. 2017;357(6356):1156–1160. doi:10.1126/science.aah5043.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L. et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Sci. 2015;350(6264):1084–1089. doi:10.1126/science.aac4255.
   PubMed Web of Science ®Google Scholar
• Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Sci. 2015;350(6264):1079–1084. doi:10.1126/science.aad1329.
   PubMed Web of Science ®Google Scholar
• Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548–563.e16. doi:10.1016/j.cell.2017.07.008.
   PubMed Web of Science ®Google Scholar
• Ramos A, Hemann MT. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer. Cell. 2017;170(3):411–413. doi:10.1016/j.cell.2017.07.018.
   PubMed Web of Science ®Google Scholar
• Mandip KC, Steer CJ. Novel mechanisms of chemoresistance by Fusobacterium nucleatum involve not so novel pathways of microRnas and autophagy. Transl Cancer Res. 2018;7(S1):S10–S15. doi:10.21037/tcr.2017.12.20.
   Google Scholar
• Zhang S, Yang Y, Weng W, Guo B, Cai G, Ma Y, Cai S. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res CR. 2019;38(1):14. doi:10.1186/s13046-018-0985-y.
   PubMedGoogle Scholar
• Liu Y, Baba Y, Ishimoto T, Tsutsuki H, Zhang T, Nomoto D, Okadome K, Yamamura K, Harada K, Eto K. et al. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer. 2021;124(5):963–974. doi:10.1038/s41416-020-01198-5.
   PubMed Web of Science ®Google Scholar
• Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal Escherichia coli. Nat Rev Microbiol. 2010;8(3):207–217. doi:10.1038/nrmicro2298.
   PubMed Web of Science ®Google Scholar
• Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol. 2010;8(1):26–38. doi:10.1038/nrmicro2265.
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Khilkin M, Kerjaschki D, Schreiber S, Ortner M, Weber J, Lochs H. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology. 1998;115(2):281–286. doi:10.1016/S0016-5085(98)70194-5.
   PubMed Web of Science ®Google Scholar
• Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology. 2004;127(1):80–93. doi:10.1053/j.gastro.2004.03.054.
   PubMed Web of Science ®Google Scholar
• Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, Pezet D, Bonnet R, Battista JR. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PloS ONE. 2013;8(2):e56964. doi:10.1371/journal.pone.0056964.
   PubMed Web of Science ®Google Scholar
• Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL. et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Sci. 2018;359(6375):592–597. doi:10.1126/science.aah3648.
   PubMed Web of Science ®Google Scholar
• Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, Campbell BJ, Abujamel T, Dogan B, Rogers AB. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Sci. 2012;338(6103):120–123. doi:10.1126/science.1224820.
   PubMed Web of Science ®Google Scholar
• Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, Déchelotte P, Bonnet R, Pezet D, Darfeuille-Michaud A. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(4):859–867. doi:10.1158/1078-0432.CCR-13-1343.
   PubMed Web of Science ®Google Scholar
• Cougnoux A, Dalmasso G, Martinez R, Buc E, Delmas J, Gibold L, Sauvanet P, Darcha C, Déchelotte P, Bonnet M. et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut. 2014;63(12):1932–1942. doi:10.1136/gutjnl-2013-305257.
   PubMed Web of Science ®Google Scholar
• Cougnoux A, Delmas J, Gibold L, Faïs T, Romagnoli C, Robin F, Cuevas-Ramos G, Oswald E, Darfeuille-Michaud A, Prati F. et al. Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. Gut. 2016;65(2):278–285. doi:10.1136/gutjnl-2014-307241.
   PubMed Web of Science ®Google Scholar
• Faïs T, Delmas J, Barnich N, Bonnet R, Dalmasso G. Colibactin: more than a New Bacterial Toxin. Toxins. 2018;10(4):10. doi:10.3390/toxins10040151.
   Web of Science ®Google Scholar
• Vizcaino MI, Crawford JM. The colibactin warhead crosslinks DNA. Nat Chem. 2015;7(5):411–417. doi:10.1038/nchem.2221.
   PubMed Web of Science ®Google Scholar
• Nougayrède J-P, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Sci. 2006;313(5788):848–851. doi:10.1126/science.1127059.
   PubMed Web of Science ®Google Scholar
• Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède J-P. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A. 2010;107(25):11537–11542. doi:10.1073/pnas.1001261107.
   PubMed Web of Science ®Google Scholar
• Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM, Nomburg J, Gurjao C, Manders F, Dalmasso G, Stege PB. et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature. 2020;580(7802):269–273. doi:10.1038/s41586-020-2080-8.
   PubMed Web of Science ®Google Scholar
• Wang M-L, Chiou S-H, Wu C-W. Targeting cancer stem cells: emerging role of nanog transcription factor. OncoTargets Ther. 2013;6:1207–1220. doi:10.2147/OTT.S38114.
   PubMed Web of Science ®Google Scholar
• Mohiuddin IS, Wei S-J, Kang MH. Role of OCT4 in cancer stem-like cells and chemotherapy resistance. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165432. doi:10.1016/j.bbadis.2019.03.005.
   PubMed Web of Science ®Google Scholar
• Walcher L, Kistenmacher A-K, Suo H, Kitte R, Dluczek S, Strauß A, Blaudszun A-R, Yevsa T, Fricke S, Kossatz-Boehlert U. Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 2020;11:1280. doi:10.3389/fimmu.2020.01280.
   PubMed Web of Science ®Google Scholar
• Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8(5):486–498. doi:10.1016/j.stem.2011.04.007.
   PubMed Web of Science ®Google Scholar
• Weiswald L-B, Bellet D, Dangles-Marie V. Spherical cancer models in tumor biology. Neoplasia N Y N. 2015;17(1):1–15. doi:10.1016/j.neo.2014.12.004.
   PubMed Web of Science ®Google Scholar
• Rotem A, Janzer A, Izar B, Ji Z, Doench JG, Garraway LA, Struhl K. Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. Proc Natl Acad Sci U S A. 2015;112(18):5708–5713. doi:10.1073/pnas.1505979112.
   PubMed Web of Science ®Google Scholar
• Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Sci. 1998;282(5391):1145–1147. doi:10.1126/science.282.5391.1145.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676. doi:10.1016/j.cell.2006.07.024.
   PubMed Web of Science ®Google Scholar
• Munro MJ, Wickremesekera SK, Peng L, Tan ST, Itinteang T. Cancer stem cells in colorectal cancer: a review. J Clin Pathol. 2018;71(2):110–116. doi:10.1136/jclinpath-2017-204739.
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–629. doi:10.1038/nrclinonc.2017.44.
   PubMed Web of Science ®Google Scholar
• Jeter CR, Yang T, Wang J, Chao H-P, Tang DG. Concise review: NANOG in cancer stem cells and tumor development: an update and outstanding questions. Stem Cells Dayt Ohio. 2015;33(8):2381–2390. doi:10.1002/stem.2007.
   PubMed Web of Science ®Google Scholar
• Lathia JD, Liu H. Overview of cancer stem cells and stemness for community oncologists. Target Oncol. 2017;12(4):387–399. doi:10.1007/s11523-017-0508-3.
   PubMed Web of Science ®Google Scholar
• Dahan L, Sadok A, Formento J-L, Seitz JF, Kovacic H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 2009;158(2):610–620. doi:10.1111/j.1476-5381.2009.00341.x.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations. Sci Transl Med. 2016;8(328):328rv4. doi:10.1126/scitranslmed.aad7118.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13(3):143–158. doi:10.1038/nrclinonc.2015.209.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x.
   PubMed Web of Science ®Google Scholar
• Jin M-Z, Jin W-L. The updated landscape of tumor microenvironment and drug repurposing. Sig Transduct Target Ther. 2020;5(1):1–16. doi:10.1038/s41392-020-00280-x.
   PubMed Web of Science ®Google Scholar
• Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol. 2012;10(10):717–725. doi:10.1038/nrmicro2873.
   PubMed Web of Science ®Google Scholar
• Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver–passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10(8):575–582. doi:10.1038/nrmicro2819.
   PubMed Web of Science ®Google Scholar
• Cummins J, Tangney M. Bacteria and tumours: causative agents or opportunistic inhabitants? Infect Agent Cancer. 2013;8(1):11. doi:10.1186/1750-9378-8-11.
   PubMedGoogle Scholar
• Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, Kroemer G. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015;7(271). doi:10.1126/scitranslmed.3010473.
   Web of Science ®Google Scholar
• Gagnaire A, Nadel B, Raoult D, Neefjes J, Gorvel J-P. Collateral damage: insights into bacterial mechanisms that predispose host cells to cancer. Nat Rev Microbiol. 2017;15(2):109–128. doi:10.1038/nrmicro.2016.171.
   PubMed Web of Science ®Google Scholar
• Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host & Microbe. 2014;15(3):317–328. doi:10.1016/j.chom.2014.02.007.
   PubMed Web of Science ®Google Scholar
• Gagnière J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, Bringer M-A, Pezet D, Bonnet M. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016;22(2):501–518. doi:10.3748/wjg.v22.i2.501.
   PubMed Web of Science ®Google Scholar
• Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. 2017;18(1):18. doi:10.3390/ijms18010197.
   Web of Science ®Google Scholar
• Allen J, Sears CL. Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development. Genome Med. 2019;11(1):11. doi:10.1186/s13073-019-0621-2.
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715. doi:10.1016/j.cell.2008.03.027.
   PubMed Web of Science ®Google Scholar
• Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Sci. 2003;300(5624):1430–1434. doi:10.1126/science.1081919.
   PubMed Web of Science ®Google Scholar
• Hoy B, Löwer M, Weydig C, Carra G, Tegtmeyer N, Geppert T, Schröder P, Sewald N, Backert S, Schneider G. et al. Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E-cadherin to disrupt intercellular adhesion. EMBO Rep. 2010;11(10):798–804. doi:10.1038/embor.2010.114.
   PubMed Web of Science ®Google Scholar
• Liou G-Y. CD133 as a regulator of cancer metastasis through the cancer stem cells. Int J Biochem Cell Biol. 2019;106:1–7. doi:10.1016/j.biocel.2018.10.013.
   PubMed Web of Science ®Google Scholar
• Ghosh K, Capell BC. The senescence-associated secretory phenotype: critical effector in skin cancer and aging. J Invest Dermatol. 2016;136(11):2133–2139. doi:10.1016/j.jid.2016.06.621.
   PubMed Web of Science ®Google Scholar
• Ito M, Kanno S, Nosho K, Sukawa Y, Mitsuhashi K, Kurihara H, Igarashi H, Takahashi T, Tachibana M, Takahashi H. et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137(6):1258–1268. doi:10.1002/ijc.29488.
   PubMed Web of Science ®Google Scholar
• Secher T, Samba-Louaka A, Oswald E, Nougayrède J-P, Sherman M. Escherichia coli producing colibactin triggers premature and transmissible senescence in mammalian cells. PloS ONE. 2013;8(10):e77157. doi:10.1371/journal.pone.0077157.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. doi:10.1038/nrm3758.
   PubMed Web of Science ®Google Scholar
• Morel A-P, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A, Klefstrom J. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PloS ONE. 2008;3(8):e2888. doi:10.1371/journal.pone.0002888.
   PubMed Web of Science ®Google Scholar
• Prieto-Vila M, Takahashi R-U, Usuba W, Kohama I, Ochiya T. Drug resistance driven by cancer stem cells and their niche. Int J Mol Sci. 2017;18(12):18. doi:10.3390/ijms18122574.
   Web of Science ®Google Scholar
• Lopès A, Billard E, Casse AH, Villéger R, Veziant J, Roche G, Carrier G, Sauvanet P, Briat A, Pagès F. et al. Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer. Int J Cancer. 2020;146(11):3147–3159. doi:10.1002/ijc.32920.
   PubMed Web of Science ®Google Scholar